Etsy exploded 88% out of the gate, giving it the best first-day return for a tech IPO in over a year. Cancer immunotherapy biotech Aduro Biotech flew up 147%, the year's third IPO to more than double on day one.
This past week was the second largest of 2015...read more
Aduro Biotech (ADRO) is the latest biotech IPO to soar on its public market debut, as the immunotherapy developer gained over 100%. Aduro boasts impressive backers, a large market opportunity and promising results from its Phase 2a trial for pancreatic...read more
Aduro Biotech, which is developing two immunotherapy platforms for pancreatic and other cancers, raised $119 million by offering 7 million shares at $17; the company had originally proposed to sell 5 million shares at a $14 to $16 range before upsizing the deal...read more
Aduro Biotech, which is developing two immunotherapy platforms for pancreatic and other cancers, raised the proposed deal size for its upcoming IPO on Tuesday. The Berkeley, CA-based company now plans to raise $119 million by offering 7 million shares at $17 per...read more
US IPO Weekly Recap: 7 IPOs see Etsy vault 70%, proving vintage is in vogue
Etsy exploded 88% out of the gate, giving it the best first-day return for a tech IPO in over a year. Cancer immunotherapy biotech Aduro Biotech flew up 147%, the year's third IPO to more than double on day one. This past week was the second largest of 2015...read more
Aduro Biotech soars 100% on IPO
Aduro Biotech (ADRO) is the latest biotech IPO to soar on its public market debut, as the immunotherapy developer gained over 100%. Aduro boasts impressive backers, a large market opportunity and promising results from its Phase 2a trial for pancreatic...read more
Pancreatic cancer biotech Aduro prices upsized IPO at $17, above its original range
Aduro Biotech, which is developing two immunotherapy platforms for pancreatic and other cancers, raised $119 million by offering 7 million shares at $17; the company had originally proposed to sell 5 million shares at a $14 to $16 range before upsizing the deal...read more
Pancreatic cancer biotech Aduro upsizes shares and increases proposed IPO price
Aduro Biotech, which is developing two immunotherapy platforms for pancreatic and other cancers, raised the proposed deal size for its upcoming IPO on Tuesday. The Berkeley, CA-based company now plans to raise $119 million by offering 7 million shares at $17 per...read more